Detalles de la búsqueda
1.
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
Lancet
; 401(10371): 105-117, 2023 01 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36495879
2.
Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Endocr Pract
; 27(9): 886-893, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581327
3.
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Drug Saf
; 46(10): 927-949, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552439
4.
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.
Cancers (Basel)
; 13(8)2021 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33919570
5.
Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors.
Curr Med Res Opin
; 36(8): 1363-1373, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32544344
6.
Corrigendum to "A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants" [Clinical Therapeutics 40 (2018) 719-732].
Clin Ther
; 40(9): 1618, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30153946
Resultados
1 -
6
de 6
1
Próxima >
>>